55279-29-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-pyridine-4-carbaldehyde is used as a pharmaceutical intermediate for the synthesis of various drugs and drug candidates. Its presence in the molecular structure can contribute to the biological activity and therapeutic effects of the final drug product.
Used in the Synthesis of Hydroxyquinolin-2(1H)-ones:
3-Amino-pyridine-4-carbaldehyde is used in the preparation of hydroxyquinolin-2(1H)-ones and their derivatives. These compounds have potential applications in treating cognitive-related disorders and neuropathic pain disorders. The unique chemical structure of 3-amino-pyridine-4-carbaldehyde allows for the development of novel therapeutic agents that can target specific neurological conditions.

InChI:InChI=1/C6H6N2O/c7-6-3-8-2-1-5(6)4-9/h1-4H,7H2

Upstream product

• 116026-95-0 3--4-pyridinecarboxaldehyde 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 
• 14208-83-4 ethyl 3-aminopyridine-4-carboxylate 
• 103698-10-8 methyl 3-nitropyridine-4-carboxylate 
• 55279-30-6 methyl 3-aminoisonicotinate 
• 1352037-93-4 N-methoxy-N-methyl 3-amino-isonicotinamide 
• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 4664-01-1 3,4-pyridinedicarboximide 
• 152398-05-5 (3-amino-pyridin-4-yl)methanol 

Downstream Products

• 316155-87-0 2-carboxy-(1,6)-naphthyridine 
• 316156-03-3 8-(4'-amino-biphenyl-4-ylmethyl)-5,6,7,8-tetrahydro-[1,7]naphthyridin-2-ylamine 
• 316155-95-0 2-tert-butoxycarbonylamino-8-(4-hydroxy-benzyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 316156-07-7 2-amino-8-(4'-amino-biphenyl-4-ylmethyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid tert-butyl ester 
• 316155-91-6 8-(4-benzyloxy-benzyl)-2-tert-butoxycarbonylamino-8H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 316155-99-4 2-tert-butoxycarbonylamino-8-(4'-nitro-biphenyl-4-ylmethyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 863785-91-5 2-phenyl-[1,7]naphthyridin-3-ol 
• 1352037-95-6 3-phenyl-2-(pyridin-4-yl)-1,7-naphthyridine 
• 1427555-52-9 1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid hydrochloride 
• 1427555-54-1 4-({1-[1-(4-chlorophenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl}carbonyl)morpholine 
• 55234-64-5 2-oxo-1,2-dihydro-[1,7]naphthyridine-3-carboxylic acid ethyl ester 
• 1609355-78-3 C₁₄H₁₀ClN₃ 
• 1609355-77-2 2-(2-chloro-5-nitrophenyl)-1,7-naphthyridine 
• 1427588-42-8 3-cyclopropyl-1-({4-[1-(4-methylphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methyl)urea 

Relevant academic research and scientific papers

BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE

The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is -NR3aC(O)-, etc. wherein R3a is hydrogen atom or C1-6 alkyl group; Cy1 is the following group of formula (11), etc.; ring Q2 is optionally-substituted benzene ring, etc.; n and m are indepndently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR5, etc.; R5 is hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; R4 is, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes

Synthesis of novel 1,7-naphthyridines by Friedlaender condensation of pyridine substrates

The general ability of appropriate pyridyl compounds (aldehyde or ketone) to undergo Friedlaender condensation to give different 1,7-naphthyridines has been demonstrated. 2,4-Disubstituted 1,7-naphthyridine 8 was prepared from 3-amino-4-acetylpyridine (6) and ketone 4 (82%). The Friedlaender self-condensation of pyridyl substrate 6 is reported, as well. The dimer product, 2-(3-aminopyridin-4-yl)-4-methyl-1,7-naphthyridine (7), was obtained in 97% yield. 2-Aryl-and 2,3-diaryl-1,7-naphthyridines (16-18) were prepared from 3-aminoisonicotinaldehyde (13) and arylketones 4, 14, and 15 (28-71%). The key substrates 6 and 13 are readily available via the improved pyridine nitration method. Copyright

PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient.

COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.

Novel non-imidazole compounds

Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.

INDOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS

Disclosed are novel compounds of the formula I wherein M1 is CH or N and M2 is C(R3) or N; R1 is optionally substituted indolyl or an aza derivative thereof; R2 is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I in combination with a H1 receptor antagonist.

Synthesis and regioselective alkylation of 1,6- and 1,7-naphthyridines

A regioselective alkylation of naphthyridines 4a-d, through the action of ethylchloroformate and benzylstannane 5, afforded the benzyl substituted dihydronaphthyridines 3a-d. These key intermediates 3a-d were transformed into the desired targets 2a-d in seven steps. (C) 2000 Elsevier Science Ltd.

Synthesis of Some Benzonaphthyridines and Benzonaphthyridines

Pfitzinger (1-benzylpiperidin-4-one with 7-methylisatin) and Friedlaender (3-aminopyridine-4-carbaldehyde with 2-methylcyclohexanone) syntheses, respectively, were used to prepare the title "azaacridines" containing a methyl substituent peri to the centra